ProfileGDS5678 / 1435766_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 64% 68% 64% 70% 57% 65% 63% 65% 64% 67% 71% 67% 62% 62% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.852364
GSM967853U87-EV human glioblastoma xenograft - Control 24.1622968
GSM967854U87-EV human glioblastoma xenograft - Control 33.8660664
GSM967855U87-EV human glioblastoma xenograft - Control 44.4392970
GSM967856U87-EV human glioblastoma xenograft - Control 53.4250557
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.9319965
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.8553763
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.9298165
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.8238464
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.0948367
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.4161571
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.1060367
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.7041162
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.7123862